Corbus Deck Marks First TEMPO-1 Patient Dosed, Targets 2H 2028 Filing For CRB-701

The October presentation shows a head and neck cancer study as under way and lists a first-half 2028 interim response readout.

Share
Corbus Deck Marks First TEMPO-1 Patient Dosed, Targets 2H 2028 Filing For CRB-701

Corbus Pharmaceuticals updated its investor presentation in an 8-K filed Thursday, marking the first patient dosed in TEMPO-1, the registrational study of CRB-701 in second-line oropharyngeal cancer, in September 2026. The deck's milestones slide lists a potential BLA filing, an FDA approval application, for the second half of 2028.

What the deck adds

The presentation shows the September commencement of the registrational study as completed. The company's earlier 8-Ks did not carry that milestone.

The same slide targets an interim response-rate readout in second-line oropharyngeal cancer in the first half of 2028, followed by the potential BLA filing in the second half of 2028. The pipeline slide also shows the topline response-rate data for first-line patients expected in the first quarter of 2027.

The deck estimates about 14,000 patients are eligible for second-line oropharyngeal cancer treatment.

The filing is an Item 7.01 disclosure, which the company says is furnished rather than filed with the SEC.

How TEMPO-1 is built

The study enrolls patients with recurrent oropharyngeal cancer who have had prior platinum therapy and anti-PD-(L)1 treatment. They are randomized one-to-one at 3.6 mg/kg: about 125 on CRB-701 and about 125 on investigator's choice therapy.

Response rate is the primary measure for accelerated approval, and overall survival is the primary measure for full approval. The design includes an interim analysis that can re-estimate sample size, and a seamless move from Phase 2 to Phase 3.

The dose rests on earlier data: the deck shows a 43% response rate at 3.6 mg/kg in oropharyngeal cancer (9 of 21 patients), from an April 1, 2026 data cut that the company first reported on May 26.

What is repeated, and what is next

Much of the deck repeats earlier material. The first-quarter 2027 data for CRB-701 plus pembrolizumab in first-line patients and the first-half 2027 start of a Phase 2 study of the obesity drug CRB-913 were shown on September 14. So was the cash figure of $118 million as of June 30, 2026.

In Thursday trading, as of 10:31 a.m. ET, CRBP shares were at $4.30, about 2% below the prior close of $4.41.

Next on the schedule: additional CRB-913 Phase 1b data at ObesityWeek in November 2026.

The first dated data point after November's ObesityWeek is the first-line CRB-701 readout, listed for the first quarter of 2027.

Sources